Rocket’s RP-A501 Restarts Post-Fatality, But Pivotal Hopes Rest on Just Three Patients' Safety Data

Rocket's Danon Gene Therapy Shows Safety Post-Protocol Change

Rocket Pharmaceuticals has safely treated three patients with its one-time Danon disease gene therapy, RP-A501, during a Phase II study following a protocol amendment. The amendment was triggered by a patient death linked to capillary leak syndrome, which occurred after Rocket added a complement C3 inhibitor to the treatment regimen without informing investors. Since the US FDA approved the relaunch of the pivotal trial (NCT06092034) in August 2025, the three dosed patients received a recalibrated dose alongside an immunosuppressive combination of rituximab, sirolimus, and corticosteroids. Rocket reports no cases of capillary leak syndrome, blood vessel damage, or other serious adverse events post-amendment, and is now discussing with the FDA how to complete the trial promptly.

• The Phase II study for RP-A501 in Danon disease was relaunched in August 2025 following a protocol amendment. This change was prompted by a patient fatality due to capillary leak syndrome, which occurred after an unannounced addition of a complement C3 inhibitor. Since the amendment, three patients have been safely treated with a recalibrated dose and an immunosuppressive regimen, with no observed cases of capillary leak syndrome, blood vessel damage, or other serious adverse events.
• The recalibrated Phase II dose was selected to deliver potency consistent with the dose that demonstrated meaningful efficacy in Phase I, while optimizing the benefit-risk profile. This recalibration accounts for a higher proportion of full capsids in the current drug product and was developed in consultation with leading experts and the FDA. Rocket's CMO anticipates this dose will preserve RP-A501’s therapeutic potential.
• Rocket Pharmaceuticals is in discussions with the FDA to determine the best path forward for treating additional patients and completing the pivotal trial. The company aims for this Phase II study to form the basis of a possible approval for RP-A501. If approved, RP-A501 would be the first treatment for Danon disease, a rare inherited condition caused by a LAMP2 gene mutation, potentially adding to Rocket's portfolio after the approval of Kresladi.

RP-A501's Safety Profile: A Pivotal Update in Danon Disease

RP-A501, a recombinant adeno-associated virus serotype 9 vector encoding the LAMP2B transgene, has been evaluated in a phase 1 study as a single-infusion gene therapy for Danon disease—a condition for which no directed therapies previously existed beyond heart transplantation. The study enrolled seven male patients (five aged 15 years or older and two aged 11–14 years), all of whom received a transient immunomodulatory regimen comprising prednisone, tacrolimus or sirolimus, and rituximab alongside the single RP-A501 infusion. Follow-up spanned 24 to 54 months, incorporating interim data from an ongoing long-term extension study, with no instances of treatment discontinuation given the one-time dosing paradigm.

Regarding tolerability, notable adverse events included one case of grade 4 complement-mediated thrombotic microangiopathy accompanied by thrombocytopenia and acute kidney injury, and three cases of grade 3 glucocorticoid-related exacerbation of Danon disease-associated skeletal myopathy. Additionally, one patient with pre-existing left ventricular systolic dysfunction at baseline experienced progressive heart failure and required cardiac transplantation five months post-infusion. Despite these serious events, all seven patients remained alive at the 24- to 54-month assessment, with complete resolution of associated side effects.

From a broader safety and efficacy standpoint, a single infusion of RP-A501 appeared to be well tolerated overall and was associated with detectable cardiac LAMP2 protein expression along with signals of clinical improvement over the follow-up period. Among the six patients who had normal left ventricular ejection fraction at baseline, outcomes included reduction from baseline or stabilization of left ventricular mass index, preservation of ejection fraction, and reduction or stabilization in cardiac biomarkers—specifically troponin I and N-terminal pro-B-type natriuretic peptide. It should be noted that this phase 1 study did not include a standard-of-care comparator arm, an important consideration when contextualizing these findings within the broader treatment landscape for Danon disease.

Unpacking the Genetic Roots of Danon Disease

Danon disease is an X-linked dominant disorder caused by mutations in the LAMP2 gene, leading to a deficiency in the lysosome-associated membrane protein 2. The specific loss of the LAMP-2B isoform, which is predominantly expressed in cardiomyocytes and plays a key role in macroautophagy, is central to the disease phenotype. This genetic defect results in defective lysosomal function and an arrest in the autophagic process. Consequently, cells are unable to efficiently clear cytoplasmic components, leading to a characteristic accumulation of autophagic vacuoles and glycogen. This impairment of autophagosome-lysosome fusion disrupts cellular homeostasis and is a foundational element of the disease's pathology.

The cellular consequences of LAMP-2 deficiency are particularly pronounced in cardiomyocytes and drive the cardiac pathology. Studies using patient-derived iPSC-cardiomyocytes demonstrate that impaired autophagic flux leads to key features of heart failure, such as increased cell size, elevated expression of natriuretic peptides, and abnormal calcium handling. This autophagic stress is directly linked to significant mitochondrial dysfunction, causing excessive oxidative stress and apoptosis. The resulting accumulation of reactive oxygen species (ROS) leads to the over-activation of calcium/calmodulin-dependent protein kinase IIδ (CaMKIIδ), a critical mechanism that promotes sarcomere disarrangement, impaired calcium recycling, and arrhythmogenesis, thereby recapitulating the clinical cardiac phenotype.

While cardiomyopathy is the primary cause of morbidity, the disease manifests systemically, with mouse models showing vacuolation in pancreatic, hepatocytic, and endothelial cells, as well as dysfunction in granulocytes and monocytes. In response to chronically impaired autophagy, cells activate the proteasome as a compensatory degradation pathway. However, modulating autophagy has produced paradoxical results in preclinical models; stimulation via exercise, caloric restriction, or rapamycin aggravates the disease and promotes dilated cardiomyopathy. In contrast, inhibiting autophagy is better tolerated but not curative, underscoring the complex and delicate nature of managing cellular clearance pathways in Danon disease.

Navigating the Pivotal Phase II Trial for RP-A501

The pivotal Phase I trial for RP-A501 (NCT03882437) was designed to evaluate the safety and preliminary efficacy of this gene therapy in male patients with Danon disease. The single-arm study administered a one-time infusion of RP-A501, a recombinant adeno-associated virus serotype 9 (rAAV9) vector carrying the LAMP2B transgene, in conjunction with a transient immunomodulatory regimen. Key design parameters and endpoints from this foundational trial are summarized below.